President Trump’s deregulatory agenda has reduced spending on pharmaceuticals by $26 billion since his inauguration, White House officials claimed in a new report Thursday.
The document, published by the Council of Economic Advisers, makes the case that government regulations were overly burdensome in getting generic drug applications reviewed for safety and brought to market. They say that having more drugs in the market, especially if they are cheaper generics, can help drive down prices.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.